The aspartic protease cathepsin-D (cath-D) is a marker of poor prognosis in breast cancer that is overexpressed and hypersecreted by human breast cancer cells. Secreted procath-D binds to the extracellular domain of the b-chain of the LDL receptor-related protein-1 (LRP1) in fibroblasts. The LRP1 receptor has an 85-kDa transmembrane b-chain and a noncovalently attached 515-kDa extracellular a-chain. LRP1 acts by (1) internalizing many ligands via its a-chain, (2) activating signaling pathways by phosphorylating the LRP1b-chain tyrosine and (3) cath-D all significantly inhibited LRP1 RIP by preventing LRP1b-CTF production. Thus, cath-D inhibits LRP1 RIP independently of its catalytic activity by blocking the first cleavage. As cath-D triggers fibroblast outgrowth by LRP1, we propose that cath-D modulates the growth of fibroblasts by inhibiting LRP1 RIP in the breast tumor microenvironment.
Introduction
The lysosomal aspartic protease cathepsin-D (cath-D) is overexpressed and abundantly secreted by human epithelial breast cancer cells Rochefort and Liaudet-Coopman, 1999; Liaudet-Coopman et al., 2006) . This overproduction in breast cancer is correlated with a poor prognosis (Ferrandina et al., 1997; Foekens et al., 1999; Rodriguez et al., 2005) . Human cath-D is synthesized as a 52-kDa precursor that is rapidly converted in the endosomes to form an active, 48-kDa, single-chain intermediate, and then in the lysosomes into the fully active mature protease, composed of a 34-kDa heavy chain and a 14-kDa light chain (Gieselmann et al., 1985) . The overexpression of cath-D in breast cancer cells leads to the hypersecretion of the 52-kDa pro-cath-D into the extracellular environment (Vignon et al., 1986; Capony et al., 1989; Fusek and Vetvicka, 1994) . Cath-D affects both the cancer cells and the stromal cells of the tumor microenvironment. Human pre-pro-cath-D cDNA transfected in cancer cells promotes cancer cell proliferation, tumor angiogenesis, and tumor growth and metastasis (Glondu et al., 2001; Berchem et al., 2002) . Human pre-pro-cath-D cDNA transfected in cath-DÀ/À MEF (mouse embryonic fibroblast) cells induces fibroblast outgrowth (LaurentMatha et al., 2005) . Inhibition of cath-D expression in breast cancer cells decreases tumor growth and metastasis Ohri et al., 2007; Vashishta et al., 2007) . Human secreted pro-cath-D stimulates breast cancer cell proliferation (Vignon et al., 1986; Fusek and Vetvicka, 1994; Vetvicka et al., 1994; Ohri et al., 2008) , fibroblast outgrowth (Laurent-Matha et al., 2005) and angiogenesis (Hu et al., 2008) . We have shown that a mutated catalytically inactive version of cath-D (D231N) is still mitogenic for tumor cells and fibroblasts (Glondu et al., 2001; Berchem et al., 2002; Laurent-Matha et al., 2005) . We recently discovered that pro-cath-D is the first ligand that binds to the extracellular domain of the b-chain of the LDL receptor-related protein-1 (LRP1) in fibroblasts (Beaujouin et al., 2010) . We also showed that cath-D promotes LRP1-dependent fibroblast outgrowth by a mechanism that is independent of its catalytic activity (Beaujouin et al., 2010) .
The LRP1 receptor consists of an 85-kDa transmembrane b-chain and a noncovalently attached 515-kDa extracellular a-chain (Strickland and Ranganathan, 2003; Lillis et al., 2005; Montel et al., 2007) . The b-chain has an extracellular domain, a transmembrane region and a cytoplasmic tail. The extracellular a-chain contains binding sites for numerous structurally diverse ligands, including lipoprotein particles, proteases and proteaseinhibitor complexes, extracellular matrix proteins, cytokines and growth factors. LRP1 has a well-defined role as a scavenger receptor mediating the endocytosis of 440 different extracellular ligands that bind to its a-chain. It delivers most, but not all, of these ligands to lysosomes for degradation (Herz and Strickland, 2001; Gonias et al., 2004; Emonard et al., 2005; May et al., 2007) . It has also been shown that LRP1 is involved in signal transduction by phosphorylation of the tyrosine in the cytoplasmic NPXY motifs of its b-chain and modulation of signaling pathways such as the MAP kinase pathway (Barnes et al., 2001 (Barnes et al., , 2003 Boucher et al., 2002; Boucher and Gotthardt, 2004; Loukinova et al., 2002; Yang et al., 2004; Newton et al., 2005; Hu et al., 2006) . More recent studies have shown that LRP1 influences gene transcription by regulated intramembrane proteolysis (RIP) of its b-chain (May et al., 2002; Kinoshita et al., 2003; von Arnim et al., 2005; Zurhove et al., 2008) . RIP is a process that involves two cleavages, as described for Notch (De Strooper et al., 1999) , APP (amyloid precursor protein) (De Strooper et al., 1998) and LRP6 (Mi and Johnson, 2007) . The first cleavage, performed by metalloproteinases (Quinn et al., 1999; Rozanov et al., 2004; Liu et al., 2009; Selvais et al., 2009 Selvais et al., , 2011 and by the membrane-associated b-secretase, BACE1 (von Arnim et al., 2005) , occurs in the extracellular region, close to the plasma membrane, and leads to shedding of the LRP1b ectodomain. This produces the membrane-associated carboxyl-terminal fragment, LRP1b-CTF, which is then cleaved by g-secretases within its transmembrane domain (Hass et al., 2009) . The LRP1b-intracellular domain, LRP1b-ICD, is released into the cytosol, where it may interact with signaling proteins, translocate to the nucleus and control gene transcription (May et al., 2002; Kinoshita et al., 2003; von Arnim et al., 2005; Zurhove et al., 2008) . We have now investigated the mechanisms by which cath-D affects the behavior of LRP1. We studied the endocytosis of pro-cath-D by LRP1 and the effect of the interaction between pro-cath-D and LRP1b on the tyrosine phosphorylation of LRP1b and/ or LRP1 RIP. Pro-cath-D was partially endocytosed by LRP1, and cath-D inhibited LRP1 RIP independently of its catalytic activity by competing with the first cleavage. Finally, we obtained evidence that the cath-D-mediated inhibition of LRP1 RIP in fibroblasts could be the mechanism by which cath-D promotes their outgrowth in the breast tumor microenvironment.
Results and discussion
Pro-cath-D is partly endocytosed by LRP1 in fibroblasts Although pro-cath-D is mainly internalized by the mannose-6-phosphate (M6P) receptors (Laurent-Matha et al., 2002 , it has been postulated that there are alternative M6P receptor-independent mechanisms (Rijnboutt et al., 1991; Capony et al., 1994; LaurentMatha et al., 2002 LaurentMatha et al., , 2005 . As we recently reported that pro-cath-D interacts with the extracellular domain of the b-chain of the LRP1 receptor in fibroblasts (Beaujouin et al., 2010) , and as LRP1 is an endocytic receptor, we investigated the role of LRP1 in the internalization of secreted pro-cath-D in fibroblasts (Figure 1 ). We first analyzed the endocytosis of S
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-radiolabelled pro-cath-D secreted by cancer cells in human mammary fibroblasts (HMF) in which endogenous LRP1 synthesis had been blocked by RNA interference ( Figure 1A ). Internalized labelled 52-kDa pro-cath-D was first transformed into a 48-kDa endosomal intermediate and then into the 34-kDa lysosomal mature enzyme ( Figure 1A , panel a, lane 1) (Capony et al., 1987) . Excess M6P prevented pro-cath-D from binding to its M6P receptors and inhibited the internalization of pro-cath-D by 82% ( Figure 1A , panel a, compare lanes 1 and 3). Thus, 18% of pro-cath-D was taken up by HMF fibroblasts in a manner that was independent of the M6P receptors ( Figure 1A , panel a, lane 3), as shown for mouse fibroblasts (Laurent-Matha et al., 2005) . Inhibiting LRP1 synthesis with siRNA ( Figure 1A , panel b) led to a 50% decrease in reminiscent pro-cath-D internalization ( Figure 1A , panel a, compare lanes 3 and 4). There was also a decrease in pro-cath-D endocytosis in LRP1-silenced fibroblasts ( Figure 1A , panel d) when uptake was measured over 18 h ( Figure 1A , panel c, compare lanes 3 and 4, and panel e for quantification). We then investigated pro-cath-D internalization by LRP1 using MEF that lacked M6P receptors ( Figure 1B Pro-cath-D and ectopic cath-D do not modulate LRP1b-chain tyrosine phosphorylation in fibroblasts The LRP1 at the plasma membrane is located in clathrin-coated pits and lipid rafts (Boucher et al., 2002; Zhang et al., 2004; Wu and Gonias, 2005) , and it has been suggested that there are LRP1-induced signal transduction pathways triggered by tyrosine phosphorylation or RIP in lipid rafts (Boucher et al., 2002 ; von Cathepsin D, endocytosis and LRP1 RIP D Derocq et al Arnim et al., 2005; Wu and Gonias, 2005) . We observed that LRP1b overproduction directs pro-cath-D to the lipid rafts (Beaujouin et al., 2010) , suggesting that cath-D modulates the tyrosine phosphorylation of LRP1, as shown for the PDGF-BB (Boucher et al., 2002; Loukinova et al., 2002; Boucher and Gotthardt, 2004; Newton et al., 2005) and CTGF (Yang et al., 2004) growth factors, the tPA serine protease (Hu et al., 2006) and in fibroblasts transformed with v-Src (Barnes et al., 2001 (Barnes et al., , 2003 . We next investigated the effect of pro-cath-D on the tyrosine phosphorylation of LRP1b in fibroblasts. HMF fibroblasts were incubated with conditioned medium containing secreted pro-cath-D (15 nM) ( Figure 2A ). Immunoblotting of anti-LRP1b immunoprecipitates with anti-phospho-tyrosine antibodies showed that pro-cath-D did not enhance the tyrosine phosphorylation of LRP1b ( Figure 2A , panel a). As a positive control, LRP1b was strongly tyrosine phosphorylated when cellular protein-tyrosine phosphatases were inhibited with orthovanadate and hydrogen peroxide ( Figure 2A, panel a) . Moreover, anti-LRP1b blots showed that the mobility of LRP1b was very different following treatment with orthovanadate and hydrogen peroxide ( Figure 2C ). However, the mobility of LRP1b in CD55À/Àcath-D cells was the same as that of CD55À/ÀSV40 cells ( Figure 2C ), indicating that LRP1b was not tyrosine phosphorylated in cells producing ectopic cath-D. We therefore conclude that secreted pro-cath-D and ectopic cath-D do not modulate the tyrosine phosphorylation of LRP1b chain in fibroblasts.
Ectopic cath-D and pro-cath-D inhibit LRP1 RIP in COS cells and in fibroblasts
As secreted pro-cath-D interacts with the extracellular domain of the LRP1b chain that is cleaved in the first step of RIP, we examined the influence of cath-D on LRP1 RIP. The ectodomain of the LRP1b chain is cleaved by metalloproteinases (Quinn et al., 1999; Liu et al., 2009; Selvais et al., 2009 Selvais et al., , 2011 and the membrane-associated b-secretase BACE1 (von Arnim et al., 2005) during RIP to generate the membraneassociated 25-kDa LRP1-CTF fragment. LRP1b-CTF then becomes a substrate of intramembrane g-secretases to produce cytoplasmic LRP1b-ICD. This, in turn, diffuses to the nucleus, where it modulates transcription (May et al., 2002; Kinoshita et al., 2003; von Arnim et al., 2005; Zurhove et al., 2008) . As pro-cath-D interacts with the extracellular part of LRP1b at the surface of fibroblasts, we studied the influence of cath-D on the first cleavage of LRP1 RIP (LRP1b-CTF production) (Figure 3) . We used both wild-type and catalytically inactive cath-D to assess the role of cath-D proteolytic activity. We also measured LRP1b-CTF production in cells treated with the g-secretase inhibitor DAPT, which blocked the cleavage of LRP1b-CTF into LRP1b-ICD by g-secretases, in order to analyze the first cleavage of RIP. We first investigated LRP1b-CTF production in COS cells co-transfected with MycLRP1b and empty vector (control), cath-D or Figure 3B, panel b) . Thus, cath-D seems to inhibit RIP by interfering with the first cleavage of LRP1 by a mechanism that is independent of its catalytic activity. We checked these results by investigating the effect of recombinant proteolytically inactive fibroblasts ( Figure 3C, panel a) . Extracellular proteolytically inactive D231N pro-cath-D significantly inhibited LRP1b-CTF production ( Figure 3C, panel b) . These findings therefore indicate that pro-cath-D inhibits the first cleavage of LRP1 RIP by a mechanism that is independent of its catalytic activity. As a result we investigated the effect of cath-D and its proteolytically inactive counterpart on the concentration of LRP1b-ICD. We suspected that this fragment was rapidly degraded in cells, as is LRP1B (Liu et al., 2007) , because immunoblotting experiments detected no LRP1b-ICD. We therefore used a luciferase reporter assay for LRP1b-ICD production in which the chimeric transcription factor, Gal4-VP16, was fused to the carboxyterminus of LRP1 (May et al., 2002; von Arnim et al., 2005) . Both ectopic cath-D and D231N cath-D inhibited LRP1b-ICD production in a dose-dependent manner ( Figure 3D, panels a and b) . Moreover, anti-cath-D siRNA reversed the cath-D-mediated effect ( Figure 3D Cathepsin D, endocytosis and LRP1 RIP D Derocq et al also inhibited LRP1b-ICD production ( Figure 3D , panel d). Similar inhibition of LRP1b-ICD production in response to ectopic cath-D was observed in MEF cells ( Figure 3D , panel e). Thus, cath-D inhibits LRP1 RIP by a mechanism that is independent of its proteolytic activity, probably by competing with the first RIP cleavage.
Many observations have shown that LRP1 is subject to RIP. A soluble fragment of LRP1, composed of the a-chain and the extracellular part of the b-chain, has been detected in the blood stream (Quinn et al., 1997; Quinn et al., 1999) . The shedding of the LRP1b-ectodomain is thought to be catalysed by one or more membrane-associated metalloproteases (Quinn et al., 1999; Rozanov et al., 2004; Liu et al., 2009; Selvais et al., 2009 Selvais et al., ., 2011 and the membrane-associated b-secretase BACE1 (von Arnim et al., 2005). LRP1b-CTF is then cleaved by g-secretases to give cytoplasmic LRP1b-ICD (May et al., 2002) . LRP1b-ICD alone is located in the nucleus and may be associated with the adaptor protein Fe65 and the histone acetyltransferase Tip60 (Kinoshita et al., 2003) . LRP1b-ICD reduces the transcriptional activity of the APP/Fe65/Tip60 complex in the nucleus, suggesting that it modulates transcription (Kinoshita et al., 2003) . A few investigations have focused on the biological significance of LRP1b-ICD. Recent studies have suggested that it is involved in ischemic cell death (Polavarapu et al., 2008) and the inflammatory response (Zurhove et al., 2008) . To date, only membraneassociated proteases have been shown to participate in the RIP of LRP1 in an autocrine manner. Interestingly, our findings provide new evidence that LRP1 RIP may be also modulated via a paracrine loop. The pro-cath-D secreted by cancer cells may influence the tumor 0 -AAGCUGGUGGACCAGAA-CAUC-3 0 , residues 666-684) was described previously (Bidere et al., 2003) . COS cells were transfected with pFR-Luc and CMV-b-gal with or without LRP1-GV, and plus or minus DAPT (20 mM) for 24 h (panel d). MEF cells were transfected using Nucleofector (AMAXA) with LRP1-GV, pFR-Luc and CMV-b-gal with or without cath-D vector (2 mg) (panel e). Luciferase activity was measured 48 h later (May et al., 2002) . The activity of Luciferase relative to b-galactosidase was analyzed in triplicate transfections. Mean ± s.d. of three independent experiments is shown. Po0.005 versus LRP1-GV (Student's t-test). The vectors used in the LRP1-Gal4-VP16 vector system were kindly provided by D Strickland (University of Maryland School of Medicine, Baltimore, USA). In RIP, LRP1b chain undergoes ectodomain shedding by membrane-associated proteases (metalloproteases and/or the membrane-associated b-secretase BACE1), generating the membraneassociated LRP1b-CTF fragment. LRP1b-CTF becomes a substrate for intramembrane cleavage by g-secretases, producing LRP1b-ICD, which is a nuclear transcriptional modulator. We propose that cath-D inhibits RIP-induced LRP1 signaling pathways in a manner independent of its proteolytic activity by competitively inhibiting the first cleavage, leading to decrease in LRP1b-CTF production and hence less LRP1b-ICD. The g-secretase inhibitor DAPT directly blocks LRP1b-ICD production. The reduced concentration of LRP1b-ICD due to cath-D or DAPT inhibition is correlated with stimulation of fibroblast outgrowth, suggesting that the RIP of LRP1 is implicated in the control of fibroblast growth. Cath-D and DAPT inhibit LRP1b-ICD production in HMF and stimulate HMF fibroblast invasive growth We have shown that cath-D triggers HMF outgrowth in a LRP1-dependent manner (Beaujouin et al., 2010) and the present study indicates that cath-D inhibits LRP1 RIP (Figure 3) . We analyzed the interplay between LRP1 RIP and fibroblast outgrowth by evaluating the effect of cath-D and the g-secretase inhibitor DAPT on LRP1b-ICD production and fibroblast outgrowth in HMF cells. To analyze the role of secreted pro-cath-D on HMF outgrowth, we carried out three-dimensional co-culture assays of HMF co-cultured with cath-Dtransfected 3Y1-Ad12 cancer cell lines either secreting no human pro-cath-D (control) or hyper-secreting human wild-type pro-cath-D ( Figure 4B , panel c).
To assess the role of DAPT on HMF outgrowth, 3D culture of HMF was performed in the presence of DAPT ( Figure 4B , panel b). We found that both cath-D and DAPT significantly inhibited LRP1b-ICD production in HMF fibroblasts ( Figure 4A , panels a and b). Cath-D and DAPT also stimulated HMF outgrowth ( Figure 4B , panels a and b, right). Thus, inhibiting LRP1b-ICD production may stimulate fibroblast outgrowth. These findings support the hypothesis that LRP1b-ICD restricts fibroblast outgrowth, possibly by regulating transcription. The genes modulated by LRP1b-ICD are presently unknown, although a recent report indicated that LRP1 target genes in the inflammatory response (Zurhove et al., 2008) . We therefore propose that procath-D hypersecreted by cancer cells triggers fibroblast outgrowth in breast tumor by inhibiting LRP1 RIP ( Figure 4C ). It may be particularly pertinent to identify the genes implicated in the control of fibroblast outgrowth that are regulated by LRP1b-ICD and cath-D.
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